Current Report Filing (8-k)
January 30 2017 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 26, 2017
CytoDyn Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-49908
|
|
75-3056237
|
(State or other jurisdiction
of incorporation)
|
|
(SEC
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
1111 Main Street, Suite 660
Vancouver, Washington
|
|
98660
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (360) 980-8524
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On January 30, 2017, CytoDyn Inc., a Delaware corporation (the Company),
issued a press release announcing the appointment, effective as of January 26, 2017, of Anthony D. Caracciolo as Executive Chairman of the Company. In this new capacity, Mr. Caracciolo will assume an active leadership role in the
Companys strategic planning, business development and operations. Nader Pourhassan, Ph.D., will continue to serve as President and Chief Executive Officer, reporting into Mr. Caracciolo, and Mr. Caracciolo will retain his position as
Chairman of the Board of Directors of the Company.
In connection with his appointment as Executive Chairman, Mr. Caracciolo has been replaced as
Chairman of the Compensation Committee by A. Bruce Montgomery, M.D., and as and a member of the Audit Committee by Carl C. Dockery. Mr. Caracciolo has also resigned from his position as a member of the Nominating and Governance Committee.
Mr. Caracciolos compensation as Executive Chairman will be determined by the Compensation Committee, as newly constituted following his appointment.
Item 7.01 Regulation FD Disclosure.
A copy of the press
release describing the appointment of Mr. Caracciolo as Executive Chairman is furnished as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial
Statements and Exhibits.
|
|
|
|
|
(d)
|
|
Exhibit
No.
|
|
Description.
|
|
|
|
|
|
99.1
|
|
Press Release, dated January 30, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
CytoDyn Inc.
|
|
|
|
January 30, 2017
|
|
By:
|
|
/s/ Michael D. Mulholland
|
|
|
Name:
|
|
Michael D. Mulholland
|
|
|
Title:
|
|
Chief Financial Officer
|
Exhibit Index
|
|
|
Exhibit
No.
|
|
Description.
|
|
|
99.1
|
|
Press Release, dated January 30, 2017
|
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Apr 2023 to Apr 2024